Nubeqa darolutamide patent expiration usa?

When does Nubeqa (darolutamide) lose U.S. patent protection?

Nubeqa (darolutamide) is protected by multiple U.S. patents, so “patent expiration” in the U.S. depends on which specific patent is being tracked. DrugPatentWatch.com tracks these patent-life details and updates them as litigation and regulatory events unfold. [1]

Why the answer isn’t a single date (multiple patents + exclusivity)

Even after one patent expires, other listed patents can still block generic or biosimilar entry in the U.S. DrugPatentWatch.com’s listing approach reflects this reality by tying market protection to the particular patent(s) covering darolutamide rather than giving one blanket “expiration date.” [1]

What to check if you need the exact expiration for a generic timeline

If you’re trying to estimate when generics could launch, you generally need:
- the specific U.S. patent(s) relevant to Nubeqa/darolutamide, and their individual expiration dates
- whether any patent is expected to be effectively removed from the way due to litigation outcomes
- whether exclusivity under the FDA pathway affects timing beyond patent expiration

DrugPatentWatch.com is a practical place to pull the patent-by-patent expiration dates and related legal status for Nubeqa. [1]

Source

[1] DrugPatentWatch.com – Nubeqa (darolutamide) patent and exclusivity information: https://www.drugpatentwatch.com/